Use of insulin and oral hypoglycemic medications in patients with diabetes mellitus and advanced kidney disease

Seminars in Dialysis

Volumn 17, Issue 5, 2004, Pages 365-370

  Snyder, Richard W ^a   Berns, Jeffrey S ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b PENN PRESBYTERIAN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACARBOSE; ACETOHEXAMIDE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE DERIVATIVE; CHLORPROPAMIDE; GLIBENCLAMIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN; INSULIN[B28 LYSINE B29 PROLINE]; METFORMIN; MIGLITOL; NATEGLINIDE; ORAL ANTIDIABETIC AGENT; PHENFORMIN; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLAZAMIDE; TOLBUTAMIDE; TROGLITAZONE;

AREA UNDER THE CURVE; CONGESTIVE HEART FAILURE; DIABETIC NEPHROPATHY; DIARRHEA; DISEASE ASSOCIATION; DOSE CALCULATION; DOSE RESPONSE; DRUG ABSORPTION; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG TOLERABILITY; DRUG UPTAKE; DRUG URINE LEVEL; EDEMA; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; JAUNDICE; KIDNEY FAILURE; LACTIC ACIDOSIS; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; SIDE EFFECT; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; PROGNOSIS; RENAL DIALYSIS; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 7044271016     PISSN: 08940959     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.0894-0959.2004.17346.x     Document Type: Review

References (54)

1. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 329:977-986, 1993
2. Malmberg K: Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 314:1512-1515, 1997
3. Alvestrand A: Carbohydrate and insulin metabolism in renal failure. Kidney Int Suppl 62:S48-S52, 1997
4. Mak RH: Impact of end-stage renal disease and dialysis on glycemic control. Semin Dial 13:4-8, 2000
5. Rabkin R, Ryan MP, Duckworth WC: The renal metabolism of insulin. Diabetologia 27:351-357, 1984
6. Rubenstein AH, Mako ME, Horwitz DL: Insulin and the kidney. Nephron 15:306-326, 1975
7. Rave K, Heise T, Pfutzner A, Heinemann L, Sawicki PT: Impact of diabetic nephropathy on pharmacodynamic and pharmacokinetic properties of insulin in type 1 diabetic patients. Diabetes Care 24:886-890, 2001
8. Biesenbach G, Raml A, Schmekal B, Eichbauer-Sturm G: Decreased insulin requirement in relation to GFR in nephropathic type 1 and insulin-treated type 2 diabetic patients. Diabet Med 20:642-645, 2003
9. Mak RH, DeFronzo RA: Glucose and insulin metabolism in uremia. Nephron 61:377-382, 1992
10. Charpentier G, Riveline JP, Varroud-Vial M: Management of drugs affecting blood glucose in diabetic patients with renal failure. Diabetes Metab 26(suppl 4):73-85, 2000
11. Aronoff GR, Berns JS, Brier ME, Golper TA, Morrison G, Singer I, Swan SK, Bennett WM: Drug Prescribing in Renal Failure. Dosing Guidelines for Adults, 4th ed. Philadelphia: American College of Physicians, 1999
12. Nevalainen PI, Lahtela JT, Mustonen J, Pasternack A: Subcutaneous and intraperitoneal insulin therapy in diabetic patients on CAPD. Perit Dial Int 16(suppl 1):S288-S291, 1996
13. Kirpichnikov D, McFarlane SI, Sowers JR: Metformin: an update. Ann Intern Med 137:25-33, 2002
14. Bailey CJ, Turner RC: Metformin. N Engl J Med 334:574-579, 1996
15. Scheen AJ: Clinical pharmacokinetics of metformin. Clin Pharmacokinet 30:359-371, 1996
16. Harrower AD: Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31:111-119, 1996
17. Somogyi A, Stockley C, Keal J, Rolan P, Bochner F: Reduction of metformin renal tubular secretion by cimetidine in man. Br J Clin Pharmacol 23:545-551, 1987
18. Lalau JD, Vermersch A, Hary L, Andrejak M, Isnard F, Quichaud J: Type 2 diabetes in the elderly: an assessment of metformin (metformin in the elderly). Int J Clin Pharmacol Ther Toxicol 28:329-332, 1990
19. Misbin RI, Green L, Stadel BV, Gueriguian JL, Gubbi A, Fleming GA: Lactic acidosis in patients with diabetes treated with metformin. N Engl J Med 338:265-266, 1998
20. Heupler FA Jr: Guidelines for performing angiography in patients taking metformin. Members of the Laboratory Performance Standards Committee of the Society for Cardiac Angiography and Interventions. Cathet Cardiovasc Diagn 43:121-123, 1998
21. Lalau JD, Westeel PF, Debussche X, Dkissi H, Tolani M, Coevoet B, Temperville B, Fournier A, Quichaud J: Bicarbonate haemodialysis: an adequate treatment for lactic acidosis in diabetics treated by metformin. Intensive Care Med 13:383-387, 1987
22. Lalau JD, Andrejak M, Moriniere P, Coevoet B, Debussche X, Westeel PF, Fournier A, Quichaud J: Hemodialysis in the treatment of lactic acidosis in diabetics treated by metformin: a study of metformin elimination. Int J Clin Pharmacol Ther Toxicol 27:285-288, 1989
23. Petersen KF, Krssak M, Inzucchi S, Cline GW, Dufour S, Shulman GI: Mechanism of troglitazone action in type 2 diabetes. Diabetes 49:827-831, 2000
24. Loi CM, Young M, Randinitis E, Vassos A, Koup JR: Clinical pharmacokinetics of troglitazone. Clin Pharmacokinet 37:91-104, 1999
25. Budde K, Neumayer HH, Fritsche L, Sulowicz W, Stompor T, Eckland D: The pharmacokinetics of pioglitazone in patients with impaired renal function. Br J Clin Pharmacol 55:368-374, 2003
26. Chapelsky MC, Thompson-Culkin K, Miller AK, Sack M, Blum R, Freed MI: Pharmacokinetics of rosiglitazone in patients with varying degrees of renal insufficiency. J Clin Pharmacol 43:252-259, 2003
27. Thompson-Culkin K, Zussman B, Miller AK, Freed MI: Pharmacokinetics of rosiglitazone in patients with end-stage renal disease. J Intern Med Res 30:391-399, 2002
28. Hollenberg NK: Considerations for management of fluid dynamic issues associated with thiazolidinediones. Am J Med 115(suppl 8A):111S-115S, 2003
29. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, Le Winter M, Porte D, Semenkovich CF, Smith S, Young LH, Kahn R: Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. Circulation 108:2941-2948, 2003
30. Manley HJ, Allcock NM: Thiazolidinedione safety and efficacy in ambulatory patients receiving hemodialysis. Pharmacotherapy 23:861-865, 2003
31. Gerich JE: Oral hypoglycemic agents. N Engl J Med 321:1231-1245, 1989
32. Jackson JE, Bressler R: Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 1. Drugs 22:211-245, 1981
33. Jackson JE, Bressler R: Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs 22:295-320, 1981
34. Feldman JM: Glyburide: a second-generation sulfonylurea hypoglycemic agent. History, chemistry, metabolism, pharmacokinetics, clinical use and adverse effects. Pharmacotherapy 5:43-62, 1985
35. Pearson JG, Antal EJ, Raehl CL, Gorsch HK, Craig WA, Albert KS, Welling PG: Pharmacokinetic disposition of 14C-glyburide in patients with varying renal function. Clin Pharmacol Ther 39:318-324, 1986
36. Brier ME, Bays H, Sloan R, Stalker DJ, Welshman I, Aronoff GR: Pharmacokinetics of oral glyburide in subjects with non-insulin-dependent diabetes mellitus and renal failure. Am J Kidney Dis 29:907-911, 1997
37. Jonsson A, Rydberg T, Sterner G, Melander A: Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. Eur J Clin Pharmacol 53:429-435, 1998
38. Rydberg T, Jonsson A, Roder M, Melander A: Hypoglycemic activity of glyburide (glibenclamide) metabolites in humans. Diabetes Care 17:1026-1030, 1994
39. Krepinsky J, Ingram AJ, Clase CM: Prolonged sulfonylurea-induced hypoglycemia in diabetic patients with end-stage renal disease. Am J Kidney Dis 35:500-505, 2000
40. Holstein A, Plaschke A, Hammer C, Egberts EH: Characteristics and time course of severe glimepiride- versus glibenclamide-induced hypoglycaemia. Eur J Clin Pharmacol 59:91-97, 2003
41. Holstein A, Egberts EH: Risk of hypoglycaemia with oral antidiabetic agents in patients with type 2 diabetes. Exp Clin Endocrinol Diabetes 111:405-414, 2003
42. Balant L, Zahnd G, Gorgia A, Schwarz R, Fahre J: Pharmacokinetics of glipizide in man: influence of renal insufficiency. Diabetologia 9:331-338, 1973
43. Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V: Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. Diabetologia 39:1617-1624, 1996
44. Clissold SP, Edwards C, Acarbose A: preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 35:214-243, 1988
45. Ahr HJ, Boberg M, Brendel E, Krause HP, Steinke W: Pharmacokinetics of miglitol. Absorption, distribution, metabolism, and excretion following administration to rats, dogs, and man. Arzneimittelforschung 47:734-745, 1997
46. Scheen AJ, Lefebvre PJ: Potential pharmacokinetics interference between alpha-glucosidase inhibitors and other oral antidiabetic agents. Diabetes Care 25:247-248, 2002
47. Dornhorst A: Insulinotropic meglitinide analogues. Lancet 358:1709-1716, 2001
48. Hatorp V: Clinical pharmacokinetics and pharmacodynamics of repaglinide. Clin Pharmacokinet 41:471-483, 2002
49. Marbury TC, Ruckle JL, Hatorp V, Andersen MP, Nielsen KK, Huang WC, Strange P: Pharmacokinetics of repaglinide in subjects with renal impairment. Clin Pharmacol Ther 67:7-15, 2000
50. Schumacher S, Abbasi I, Weise D, Hatorp V, Sattler K, Sieber J, Hasslacher C: Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Eur J Clin Pharmacol 57:147-152, 2001
51. Hasslacher C: Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Diabetes Care 26:886-891, 2003
52. Weaver ML, Orwig BA, Rodriguez LC, Graham ED, Chin JA, Shapiro MJ, McLeod JF, Mangold JB: Pharmacokinetics and metabolism of nateglinide in humans. Drug Metab Dispos 29:415-421, 2001
53. Inoue T, Shibahara N, Miyagawa K, Itahana R, Izumi M, Nakanishi T, Takamitsu Y: Pharmacokinetics of nateglinide and its metabolites in subjects with type 2 diabetes mellitus and renal failure. Clin Nephrol 60:90-95, 2003
54. Nagai T, Imamura M, Iizuka K, Mori M: Hypoglycemia due to nateglinide administration in diabetic patient with chronic renal failure. Diabetes Res Clin Pract 59:191-194, 2003